



27 Nov

UAM – IIB MADRID

II ENCUENTRO

DE JÓVENES INVESTIGADORES DE

CIBERONC

 #IIEJI_ONC

TRAINING & MOBILITY PROGRAM



ciberonc
Centro de Investigación Biomédica en Red
Cáncer



GOBIERNO DE ESPAÑA

MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES

ISC
Instituto de Salud Carlos III

Patrocinado por:



II ENCUENTRO DE JÓVENES INVESTIGADORES DE CIBERONC

09:00 **Registro**

09:30 **Bienvenida**

Joaquín Arribas. VHIO. *Director Científico de CIBERONC*

Amparo Cano. UAM. *Coordinadora del Programa de Formación y Movilidad*

10:00 **Programa de Tumores Gastro-Intestinales**

Chair: Noelia Tarazona

ZNF518B promotes the activation of proliferation pathways and the epithelial to mesenchymal transition phenotype in colorectal cancer cell lines. Francisco Gimeno

Unravelling the role of Nr5a2 in pancreatic cancer through inflammation. Irene Millán

10:30 **Programa de Cáncer de Mama**

Chair: Alberto Vázquez

Identification of novel mechanisms of resistance to immunotherapy in cancer. Alex Martínez

Trametinib-mediated MEK1/2 inhibition triggers ERK5 overactivation in ovarian cancer: therapeutic concerns and opportunities. Adrián Sánchez

11:00 **Pausa café – Sesión de pósteres + foto evento**

12:00 **Programa de Tumores del Tracto Respiratorio**

Chair: Elena Duréndez

Next Generation Sequencing using liquid biopsies: a non-invasive tool that allows identification of targetable alterations in lung cancer patients. Andrea Moreno

TMPRSS4: a novel prognostic indicator for the stratification of stage IA tumors and a diagnostic biomarker for NSCLC patients. Francisco Expósito

12:30 **Programa de Tumores Hematológicos**

Chair: Irene López

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment identifies CD27-negative T cells as potential source of Tumor-Reactive Lymphocytes. Cristina Pérez

IRF4-rearranged Large B-cell lymphoma (LBCL) has a genomic profile distinct to other LBCL in children and young adults. Joan Enric Ramis

- 13:00 **Programa de Tumores de Baja Prevalencia**
Chair: Ezequiel Monferrer
Cellular cytotoxicity is a form of immunogenic cell death. Luna Cordeiro
Minute
Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8 T cells. Iñaki Etxeberria
- 13:30 **Programa de Mecanismos de Progresión Tumoral**
Chair: Cristina Viera
Functional characterization of RRAS2 mutations and role of R-RAS2 in ovarian cancer. Laura Clavaín
Rho pathway landscape in cancer genomics. Rubén Fernández
- 14:00 **Comida + Sesión de pósteres**
- 15:30 **MR1: Futuras perspectivas**
Chair: Vanesa Nogales. CIBERONC
Javier Carmona. Editor en Nature Medicine
Pablo Reclusa. Project Manager en HistoGeneX
- 16:15 **Trivial**
- 16:30 **Ponente invitado**
Circulating tumour DNA analysis to guide adjuvant therapies in breast cancer
Isaac García-Murillas. The Institute of Cancer Research of London
- 17:15 **MR2: From bench to bedside**
Chair: Xosé Bustelo. Presidente de ASEICA
Amparo Cano. IIB-UAM. Investigación preclínica.
Dolors Colomer. IDIBAPS. Investigación traslacional.
Carlos Camps. FIHGUV-HGUV. Investigación clínica.
- 18:00 **Fin del acto**
- 20:30 **Cena CIBERONC-ASEICA y entrega de premios**



POSTERS SESSION

- GIT1 Colorectal cancer patient's derived organoids maintain mutational and copy number profile of the original patient's tumor
- GIT2 RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer
- GIT3 Comprehensive benchmarking of paired tumor samples for detecting copy number variations in targeted gene panels
- GIT4 Establishment and characterization of gastric cancer patient's derived organoids
- GIT5 Mutation tracking in circulating tumor DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression or CMS subtype.
- GIT6 RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology
- BC1 Trametinib-mediated MEK1/2 inhibition triggers ERK5 overactivation in ovarian cancer: therapeutic concerns and opportunities
- BC2 Understanding the role of Loxl3 in melanomagenesis
- BC3 AXL overexpression confers Trastuzumab resistance through heterodimerization with HER2 in HER2 amplified Breast Cancer models
- BC4 Defining sensitivity to HER2 targeted therapies, beyond HER2 expression
- BC5 EV20/MMAF, an anti-HER3 Antibody Drug Conjugate with antitumoral activity in HER2 positive breast cancer
- BC6 Generation of CAR T cells targeting p95HER2 for the treatment of HER2-positive breast cancer
- BC7 Gasdermin B mediates the resistance to anti-HER2 therapies through pro-survival autophagy induction in HER2+ cancer
- BC8 Role of ERK5 in the regulation of glutamine metabolism in cancer
- RTT1 Representation Learning of Complex Tissue Microenvironments in Multiplex Image Cytometry
- RTT2 Exosomes as a valuable tool for biomarkers searching in NSCLC
- RTT3 Characterization of gut microbiota in advanced non-small cell lung cancer (nscl) patients treated with immune checkpoints blockers
- RTT4 Dasatinib promotes stemness in head and neck cancer cells which is effectively suppressed by combination treatment with the mithralog EC-8042
- RTT5 Emerging role of SOX2 as early independent predictor of laryngeal cancer risk in patients with precancerous lesions beyond histopathological grading
- RTT6 Functional and clinical elucidation of the phosphatidylinositol transfer protein PIPNC1 in mutant KRAS lung adenocarcinoma
- RTT7 Analysis of immunoregulatory factors produced by lung tumorspheres: Galectin-3 as immune modulator with prognostic value in NSCLC adenocarcinoma
- HT1 Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma
- HT2 FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets
- HT3 Characterization of in situ MSCs from healthy and MM bone marrow: transcriptional modulation of the microenvironment
- HT4 Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM)
- HT5 Diffuse large B-cell lymphoma survival prognostication, a comparative analysis of Cell of Origin vs. MYC/BCL2 expression
- HT6 Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia
- HT7 Peripheral T-cell lymphoma, an unmet need and also an opportunity for learning about a complex cancer type
- LPT1 Ubiquitin-ligase FBXO32 is a key KIT-downstream effector that mediates adaptation to KIT inhibition in gastrointestinal stromal tumor
- LPT2 Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing for a differential and accurate diagnosis of bone and soft tissue tumors
- LPT3 Gelatin-based hydrogels for neuroblastoma 3D bioprinting
- LPT4 Screening signature of endometrial and ovarian cancers: options for early detection (SCREENWIDE)
- LPT5 Development and characterization of a nanosystem activated by light for treatment of pancreatic cancer
- LPT6 Evaluation of nanomedicines for cancer gene therapy making use of zebrafish models
- LPT7 Genome-wide study of salivary miRNAs as a potential non-invasive biomarkers for detection colorectal cancer
- LPT8 Connecting extracellular vesicle uptake and exosome biogenesis: intercellular communication in breast cancer cells is ITGB3-dependent
- LPT9 The relevance of endoglin on the metastatic potential of Ewing sarcoma cells
- MTP1 Increased SIX1 expression in thyroid cells promotes epithelial to mesenchymal transition
- MTP2 Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids
- MTP3 Optimization of ERK signalling by transphosphorylation across different scaffold protein species.
- MTP4 Exploiting metabolic gene expression for prostate cancer stratification
- MTP5 Different stimuli modulate PI3K/AKT & RAS/ERK pathways and biological effects in cancer
- MTP6 Gene regulatory and phenotypic effects of calcitriol and canonical WNT in human colon fibroblasts.
- MTP7 PARylation induces selective HIF-1a chromatin recruitment during hypoxia
- MTP8 Description of a feedback loop between the tumor suppressor DICER1 and thyroid transcription factors in thyroid tumorigenesis
- MTP9 Understanding the effect of PIK3CA overexpression over YAP activation in head and neck cancer
- MTP10 PARP1 inhibition and hypoxia enhance the endothelial phenotype in melanoma cells during vasculogenic mimicry
- MTP11 Development of new Rasa1 mutant mice for the study of breast cancer
- MTP12 Editing FANA-Mutations in Sporadic HNSCC Cell Lines: A New FA-HNSCC Disease Model
- MTP13 Dexamethasone and N-acetyl cysteine antenatal administration palliates organism lethality in HRas/NRas double-knockout mice
- MTP14 Development of Large Cell Neuroendocrine or Small Cell Lung Carcinoma upon inactivation of Rb1, Pten and Trp53 in lungs of Rb1 null mice
- MTP15 Regulation of ERK dimerization and nuclear transport by novel phosphorylation events